BPC-157 vs TB-500
BPC-157 and TB-500 are two of the most-studied peptides in tissue-repair and angiogenesis research. They are frequently compared, and frequently studied together, because they act through different mechanistic routes. This reference contrasts their origin and research focus.
| Aspect | BPC-157 | TB-500 |
|---|---|---|
| Origin | Pentadecapeptide derived from a gastric protein fragment | Synthetic fragment of thymosin β-4 |
| Mechanism class studied | Cytoprotection & angiogenic signaling | Actin regulation & cell migration |
| Primary research focus | Soft-tissue and gut-lining repair models | Tissue remodeling & wound-healing models |
| Often researched with | TB-500 (combination protocols) | BPC-157 (combination protocols) |
| Format / purity | Lyophilized · ≥99% HPLC | Lyophilized · ≥99% HPLC |
Different routes to the same research question
BPC-157 is studied largely for cytoprotective and angiogenic signaling, whereas TB-500 (a thymosin β-4 fragment) is studied for its role in actin regulation and cell migration. Because the routes differ, the literature often pairs them — which is why many labs investigate them as a stack.
The combination option
We also stock a combined BPC-157 + TB-500 preparation for protocols that call for both in one vial. See the recovery category for the blend and the individual compounds.
Questions
For Research Use Only. Not for human or animal consumption. The above is a neutral summary of compound class and published research context; it is not medical, dosing, or usage guidance, and has not been evaluated by the Food and Drug Administration.